Clinical trials: Clostridium Difficile Infection
Clostridia Difficile Colitis, Clostridium; Sepsis
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
A new medication, Bezlotoxumab, has been approved for treatment of recurrent Clostridium difficile diarrhea by the U.S. Food and Drug Administration. The way this new medication works, is by binding the toxin produced by C.
- Trial name
- NCT03756454
- Testing
- Bezlotoxumab, Normal Saline
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ohio State University
Patients at High Risk of Antibacterial Treatment Upon Admission
Impact of Prescription Quality, Infection Control and Antimicrobial Stewardship on Gut Microbiota Domination by Healthcare-Associated Pathogens
Extended-spectrum beta-lactamase producing Enterobacteriaceae (EPE), vancomycin-resistant enterococci (VRE) and Clostridium difficile have become a major threat to hospitalised patients worldwide.
- Trial name
- PILGRIM (NCT03765528)
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- University Hospital of Cologne
Clostridium Difficile Infection
Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum
Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C.
- Trial name
- NCT01914731
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Clostridioides Difficile Infection
Study of Clostridioides Difficile in Infants
Clostridioides difficile infection (CDI) poses an increasing threat to infant and young child health, with detection rates rising annually.
- Trial name
- NCT06788769
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Westlake University
Clostridium Difficile Infection
COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium difficile infection (CDI) is the most common cause of antibiotic associated diarrhoea in the western world. The infection causes significant diarrhoea, which in some cases can be serious and lead to secondary…
- Trial name
- COMBACTE-CDI (NCT03503474)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 3,240 people
- Sponsor
- University of Leeds
Clostridium Difficile Infection
A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile Infection
This study is a two-arm, interventional, prospective, open-label, multi-center clinical trial with randomized and non-randomized study groups to evaluate the safety and effectiveness of faecal microbiota transplantation (FMT) for…
- Trial name
- FMTREAT (NCT03053505)
- Testing
- faecal human microbiota transplant (FMT), Vancomycin or Fidaxomicin
- Where
- 3 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Sejtterapia Kozpont Kft.
Clostridial Infection, Dysbiosis
Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)
Multi-center, randomized, placebo controlled, partially blinded trial comparing the safety and efficacy of fecal microbiota transplantation versus placebo both delivered by rectal enema in subjects 18 years of age or older with…
- Conditions
- Clostridial Infection, Dysbiosis, Probiotic Therapy
- Trial name
- NCT03548051
- Testing
- Fecal Microbiota Transplantation (FMT), Saline
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
C. Difficile Infection
Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy
The investigators found that community acquired C. diff occurs in children undergoing a colonoscopy. When they were treated their symptoms got better. But, the investigators do not know if the treatment for the C.
- Trial name
- c diff (NCT01472978)
- Testing
- metronidazole
- Where
- United States
- Sponsor
- State University of New York at Buffalo
Clostridioides Difficile Infection Recurrence, FMT
FMT Capsules for rCDI
Double blind RCT study of tretment of recurrent Clostridioides difficile infection by FMT capsules.
- Trial name
- FMT CAP CDI (NCT07458984)
- Testing
- Healthy donor stool
- Where
- Finland
- Volunteers
- 76 people
- Sponsor
- Helsinki University Central Hospital
Clostridioides Difficile Infection
FMT in Initial CDI
The study explores fecal microbiota transfer via retention enema after the first clostridioides difficile episode.
- Trial name
- FinCDI (NCT05257538)
- Testing
- FMT
- Where
- Finland
- Volunteers
- 140 people
- Sponsor
- Turku University Hospital
Inflammatory Bowel Diseases, Clostridium Difficile Infections
Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients
The goal of this research is to compare alterations of gut microbiota and fecal metabolomics alterations between inflammatory bowel disease patients infected with or without Clostridioides difficile.
- Conditions
- Inflammatory Bowel Diseases, Clostridium Difficile Infections, Microtia
- Trial name
- NCT05714566
- Testing
- Clostridioides difficile toxin detection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Recurrence of Clostridium Difficile Infection
REBYOTA™ Prospective Registry
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting.
- Trial name
- ROAR (NCT05835219)
- Testing
- REBYOTA™
- Where
- 42 sites in United States
- Volunteers
- 145 people
- Sponsor
- Ferring Pharmaceuticals
Clostridium Difficile
PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
A total of 440 patients meeting enrollment criteria with a primary episode of C. Difficile Infection (CDI) will be enrolled across 3 sites.
- Trial name
- PROCLAIM (NCT03617172)
- Testing
- Misoprostol 100Mcg Tab
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt University Medical Center
Clostridium Difficile Infection
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
MET-2 clinical study is an Open label, single center, multiple dose pilot study of 19 patients. The study is designed to measure the resolution of diarrhea as well as the feasibility of administration and safety of MET-2 for the…
- Trial name
- NCT02865616
- Testing
- MET-2, Vancomycin
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- NuBiyota
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Intestinal Microbiota Transplantation in Patients Undergoing Colon Resection
This is a single-center, open-label study for safety and feasibility of IMT in patients undergoing colonic surgery. After consent, individuals of the ages of 18-75 with a history of diverticulitis or sigmoid colon cancer will be…
- Trial name
- NCT06370884
- Testing
- IMT
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Diarrhea, Clostridium Infections
Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
The purpose of this study is to evaluate the efficacy and safety of Bio-K + CL1285 versus placebo in the prevention of antibiotic-associated diarrhea in hospitalized adult patients.
- Trial name
- NCT00328263
- Testing
- Lactobacillus acidophilus CL1285 and Lactobacillus casei
- Where
- 8 sites in Canada
- Volunteers
- 472 people
- Sponsor
- Bio-K Plus International Inc.
Severe Clostridium Difficile Infection, Severe-Complicated/Fulminant Clostridium Difficile Infection
Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)
This is a randomized, open label, comparative, Phase II study to determine whether fecal microbiota transplant using Penn Microbiome Therapy products helps standard therapy to treat severe Clostridium difficile infection (C diff).
- Trial name
- NCT03970200
- Testing
- Penn Microbiome Therapy - 001, Penn Microbiome Therapy - 002, Penn Microbiome Therapy - 003
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Pennsylvania
Bacteria Infection Mechanism
Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Difficile in Infants
Clostridioides difficile (formerly C. difficile) is a bacterium found in the form of spores (a resistant form) to which patients may be exposed in a hospital environment.
- Trial name
- BBDIFF (NCT07512908)
- Testing
- cohort follow up
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics.
- Trial name
- NCT07221708
- Testing
- Vancomycin (POC)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Clostridium Difficile
Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA
Clostridium difficile (C. difficile) is a major pathogen causing serious healthcare-associated diarrheal illness in patients. Prevention of healthcare facility-onset C. difficile infection (CDI) is essential.
- Trial name
- GLORI (NCT04036058)
- Testing
- Universal gloving
- Where
- 6 sites in United States
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development